AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1328366 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as the drug of first choice
Number of subjects: 64
Study 2866059 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate (SCG; 20 mg)
Number of subjects: 10
Study 2866059 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (0.5 mg)
Number of subjects: 10
Study 2866059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg)
Number of subjects: 10
Study 2866059 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl) placebo
Number of subjects: 10
Study 26067748 — intervention group
Group type: EXPERIMENTAL
Intervention: INICC multidimensional hand hygiene approach
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Adult ICUs
Number of subjects: 13201
Study 26067748 — intervention group
Group type: COMPARATOR
Intervention: Neonatal ICUs
Number of subjects: 13201
Study 30463388 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise intensity prescription (using heart rate reserve)
Number of subjects: 38
Study 30463388 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise intensity prescription (using ventilatory threshold)
Number of subjects: 38
Study 26937863 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 6)
Number of subjects: 18
Study 26937863 — intervention group
Group type: COMPARATOR
Intervention: 2-day stored transfusion (n = 6)
Number of subjects: 18
Study 26937863 — intervention group
Group type: COMPARATOR
Intervention: 35-day stored transfusion (n = 6)
Number of subjects: 18
Study 26937863 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Normal saline, 2-day stored, 35-day stored)
Number of subjects: 18
Study 23766436 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective proxy reports of well-being
Number of subjects: 164
Study 23766436 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' life satisfaction over the last year of life
Number of subjects: 164
Study 23156846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus (FK‐506) eye ointment
Number of subjects: 24
Study 23156846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cyclosporine eye drops
Number of subjects: 24
Study 23156846 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with 0.1% FK‐506 eye ointment
Number of subjects: 24
Study 20692561 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 50
Study 20692561 — intervention group
Group type: COMPARATOR
Intervention: Besifloxacin 0.6% ophthalmic suspension
Number of subjects: 50
Study 19167587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone hydrochloride (test formulation)
Number of subjects: 20
Study 19167587 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone maleate (reference formulation)
Number of subjects: 20
Study 15695780 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging using (99m)Tc‐TRODAT‐1
Number of subjects: 76
Study 15695780 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging in PD patients
Number of subjects: 76
Study 15695780 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging in less severe PD patients
Number of subjects: 76
Study 15695780 — intervention group
Group type: COMPARATOR
Intervention: Striatal dopamine transporter (DAT) imaging in controls
Number of subjects: 76
Study 14508308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intravenous M6G
Number of subjects: 9
Study 14508308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.13 mg/kg intravenous morphine
Number of subjects: 9
Study 14508308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 9
Study 10499751 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 2% plain lidocaine and 0.5% bupivacaine with epinephrine 1:200,000
Number of subjects: 360
Study 10499751 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 1% plain lidocaine and 0.25% bupivacaine with epinephrine 1:200,000
Number of subjects: 360
Study 10499751 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: 1.5% plain lidocaine and 0.37% bupivacaine with epinephrine 1:200,000
Number of subjects: 360
Study 8973852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after the first trimester of pregnancy
Number of subjects: 28
Study 8973852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 28
Study 8973852 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 28
Study 8973852 — intervention group
Group type: COMPARATOR
Intervention: Relapse-free survival
Number of subjects: 28
Study 1866057 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐HDF (1.75 mmol/l calcium)
Number of subjects: 0
Study 1866057 — intervention group
Group type: COMPARATOR
Intervention: B‐HDF (bicarbonate-containing and calcium-free)
Number of subjects: 0
Study 1866057 — intervention group
Group type: EXPERIMENTAL
Intervention: B2‐HDF (bicarbonate-containing and calcium-free with increased ultrafiltration rate)
Number of subjects: 0
Study 30081854 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 60
Study 30081854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25732606 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led educational prevention measure
Number of subjects: 738
Study 25732606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 738
Study 25509255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI) 15 mL, twice daily for 14 days
Number of subjects: 91
Study 25509255 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 91
Study 25509255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI)
Number of subjects: 91
Study 25509255 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (20 healthy subjects)
Number of subjects: 91
Study 22721575 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1005
Study 22721575 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1005
Study 22721575 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1005
Study 22721575 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1005
Study 20458090 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended physiotherapy (60 min/d during acute care plus an unsupervised home program)
Number of subjects: 173
Study 20458090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment (2000 IU/d)
Number of subjects: 173
Study 20458090 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (30 min/d during acute care plus no home program)
Number of subjects: 173
Study 20458090 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol treatment (800 IU/d)
Number of subjects: 173
Study 18821167 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-critical stimuli presented infrequently and non-synchronously with critical target stimuli
Number of subjects: 0
Study 18821167 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-critical stimuli presented frequently and simultaneously during encoding of critical stimuli
Number of subjects: 0
Study 16285880 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fall risk assessment tool alongside nurses' clinical judgement
Number of subjects: 1080
Study 16285880 — intervention group
Group type: COMPARATOR
Intervention: Nurses' clinical judgement alone
Number of subjects: 1080
Study 12699178 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids supplementation for 15 days before surgery
Number of subjects: 40
Study 12699178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acids)
Number of subjects: 40
Study 10337452 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 45
Study 10337452 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45
Study 10337452 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (14 days)
Number of subjects: 45
Study 7574936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 145
Study 7574936 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 145
Study 7574936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 2007963 — intervention group
Group type: EXPERIMENTAL
Intervention: Portagen
Number of subjects: 50
Study 2007963 — intervention group
Group type: COMPARATOR
Intervention: Diluted cow milk
Number of subjects: 50
Study 2007963 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (Nanon)
Number of subjects: 50
Study 2007963 — intervention group
Group type: COMPARATOR
Intervention: Pregestimil
Number of subjects: 50
Study 2007963 — intervention group
Group type: COMPARATOR
Intervention: Prosobee
Number of subjects: 50
Study 7105431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (100 mg)
Number of subjects: 0
Study 7105431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral labetalol (100 mg and 200 mg)
Number of subjects: 0
Study 7105431 — intervention group
Group type: COMPARATOR
Intervention: L-dopa plus carbidopa (250 mg and 25 mg respectively every 6 h for 1 day)
Number of subjects: 0
Study 31721775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing smoking during pregnancy
Number of subjects: 8621
Study 31721775 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking in early pregnancy
Number of subjects: 8621
Study 31721775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined 1-cigarette-per-day increase in smokers
Number of subjects: 8621
Study 31721775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined 1-cigarette-per-day increase in non-smokers
Number of subjects: 8621
Study 31721775 — intervention group
Group type: COMPARATOR
Intervention: Partner smoking
Number of subjects: 8621
Study 29939056 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Social, Communication, Emotional Regulation, and Transactional Support (SCERTS) Intervention (CSI)
Number of subjects: 197
Study 29939056 — intervention group
Group type: COMPARATOR
Intervention: Usual school‐based education with autism training modules (ATM)
Number of subjects: 197
Study 28043273 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (BiPAP)
Number of subjects: 62
Study 28043273 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 62
Study 24461277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (QueaseEase, Soothing Scents, Inc, Enterprise, AL)
Number of subjects: 121
Study 24461277 — intervention group
Group type: COMPARATOR
Intervention: Unscented inhalant (placebo)
Number of subjects: 121
Study 22130317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100
Study 22130317 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100
Study 19130647 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 50% 1RM (two sets of 13 repetitions)
Number of subjects: 15
Study 19130647 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% 1RM (two sets of 8 repetitions)
Number of subjects: 15
Study 19130647 — intervention group
Group type: COMPARATOR
Intervention: Control session without exercise
Number of subjects: 15
Study 17139892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general‐epidural anaesthesia and postoperative epidural analgesia
Number of subjects: 1443
Study 17139892 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia and analgesia
Number of subjects: 1443
Study 14633068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (0.05% bethamethasone cream) twice daily for 1 month
Number of subjects: 149
Study 14633068 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo cream
Number of subjects: 149
Study 14633068 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 149
Study 11069465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 10
Study 11069465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8651535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia (IPA) with bupivacaine/lidocaine
Number of subjects: 16
Study 8651535 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution of normal saline
Number of subjects: 16
Study 1350809 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass (CPB) at mean nasopharyngeal temperature of 34.7 degrees C
Number of subjects: 34
Study 1350809 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (CPB) at mean nasopharyngeal temperature of 27.8 degrees C
Number of subjects: 34
Study 6326632 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 49
Study 6326632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31235162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)‐based weight loss program for 12 weeks
Number of subjects: 50
Study 31235162 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 women)
Number of subjects: 50
Study 31235162 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 50
Study 28503997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime television exposure during infancy (first 24 months)
Number of subjects: 0
Study 28503997 — intervention group
Group type: COMPARATOR
Intervention: Family characteristics (college-educated fathers, annual income >$50,000)
Number of subjects: 0
Study 26031289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based goal management training (GMT)
Number of subjects: 90
Study 26031289 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based education
Number of subjects: 90
Study 26031289 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 23685298 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (SES)
Number of subjects: 458
Study 23685298 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 458
Study 21544072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study 21544072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19699593 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (maximum 60mg/day)
Number of subjects: 50
Study 19699593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17302079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 0
Study 17302079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal meperidine
Number of subjects: 0
Study 17302079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine
Number of subjects: 0
Study 17302079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol
Number of subjects: 0
Study 15034108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy with conjugated estrogens and medroxyprogesterone acetate
Number of subjects: 2763
Study 15034108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 11498655 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 0
Study 11498655 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 0
Study 9620819 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown-heel measurement technique
Number of subjects: 32
Study 9620819 — intervention group
Group type: COMPARATOR
Intervention: Supine measurement technique
Number of subjects: 32
Study 9620819 — intervention group
Group type: COMPARATOR
Intervention: Paper barrier measurement technique
Number of subjects: 32
Study 9620819 — intervention group
Group type: COMPARATOR
Intervention: Neo-infantometer measurement technique
Number of subjects: 32
Study 7994449 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-trinositol
Number of subjects: 24
Study 7994449 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2723710 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20
Study 2723710 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral narcotics
Number of subjects: 20
Study 29652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin‐3‐gallate (EGCG)
Number of subjects: 96
Study 29652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin
Number of subjects: 96
Study 29652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 96
Study 29652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper easy bond (self-etch adhesive system)
Number of subjects: 96
Study 29652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (total-etch adhesive system)
Number of subjects: 96
Study 28161016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow warm humidified oxygen (HFWHO)
Number of subjects: 202
Study 28161016 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min)
Number of subjects: 202
Study 26525809 — intervention group
Group type: EXPERIMENTAL
Intervention: Axamon (ipidacrine) in addition to basic therapy (B vitamins, lipoic acid) for 6 weeks
Number of subjects: 35
Study 26525809 — intervention group
Group type: COMPARATOR
Intervention: Basic (standard) treatment (B vitamins, lipoic acid)
Number of subjects: 35
Study 25006405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tadalafil (40 mg daily for 12 months)
Number of subjects: 0
Study 25006405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21617914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 22
Study 21617914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18458355 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 16
Study 18458355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16909519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined obturator/post system
Number of subjects: 4
Study 16909519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined obturator/post with a single resin endodontic sealer/luting cement
Number of subjects: 4
Study 12888702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg once daily
Number of subjects: 1229
Study 12888702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study 11251560 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 10 sunscreen
Number of subjects: 148
Study 11251560 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen
Number of subjects: 148
Study 9008374 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct strategy (changing behavior to reduce hypocrisy)
Number of subjects: 0
Study 9008374 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation strategy (affirmation of an unrelated positive aspect of the self)
Number of subjects: 0
Study 8314497 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b (10 million units three times weekly subcutaneously for 16 weeks) after six weeks of prednisone (followed by a two week drug-free period)
Number of subjects: 50
Study 8314497 — intervention group
Group type: COMPARATOR
Intervention: High dose interferon alfa‐2b (after 24 weeks control phase)
Number of subjects: 50
Study 8314497 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b
Number of subjects: 50
Study 8314497 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (group I and II combined)
Number of subjects: 50
Study 8314497 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial non-responders
Number of subjects: 50
Study 2967932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (5 micrograms)
Number of subjects: 42
Study 2967932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (5 micrograms) plus immunoglobulin (0.25 ml/kg)
Number of subjects: 42
Study 29941402 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental moisturizing mouthwash (1 to 2 doses/day for 8 days)
Number of subjects: 128
Study 29941402 — intervention group
Group type: COMPARATOR
Intervention: Water-only (control group)
Number of subjects: 128
Study 29941402 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental moisturizing mouthwash
Number of subjects: 128
Study 28238393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (twice weekly for 12 weeks)
Number of subjects: 54
Study 28238393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for the same time period)
Number of subjects: 54
Study 24292999 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous IFN β‐1a 44 µg three times a week
Number of subjects: 517
Study 24292999 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous IFN β‐1a 44 µg once a week
Number of subjects: 517
Study 24292999 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 517
Study 22093035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% CA
Number of subjects: 1720
Study 22093035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% CA
Number of subjects: 1720
Study 22093035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% CA
Number of subjects: 1720